Lepodisiran: The RNA Therapy Targeting a Stubborn Cardiovascular Risk

Researchers are investigating a small interfering RNA to directly lower lipoprotein(a), an independent risk factor linked to atherosclerotic cardiovascular disease. With a high prevalence of elevated lipoprotein(a) in the general population, standard approaches lacked a direct reducing effect, leaving doctors searching for a more effective tool. Now, a novel agent called lepodisiran has emerged from early-phase trials designed to assess its safety and efficacy.

The Rationale Behind Lepodisiran

Elevated lipoprotein(a), or Lp(a), is an established, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Given the significant burden of ASCVD and the high prevalence of elevated Lp(a) in the general population, researchers recognised a clear need for novel therapeutic drugs.

Older methods relied on broad strategies that lacked a direct Lp(a) reducing effect. Doctors could only attempt to manage overall cardiovascular risk, while leaving the specific Lp(a) threat largely unaddressed. This glaring gap in cardiovascular care necessitated a highly targeted approach.

Silencing the RNA

The new approach uses small interfering RNA (siRNA) specifically targeting Lp(a). Phase 1 and 2 randomised control trials, including the ALPACA study, evaluated the safety and efficacy of this targeted mechanism.

The early trials focused on two specific parameters in a controlled setting:

• Safety assessments of the siRNA intervention.
• Efficacy assessments regarding its direct Lp(a) reducing effect.

Initial data show that lepodisiran demonstrates a direct Lp(a) reducing effect in trial participants. By directly targeting the RNA, the drug aims to achieve a precision that older, broader lipid strategies lacked.

What the Data Leaves Unanswered

Despite evidence of a direct reducing effect in early trials, the current data do not yet prove that targeting Lp(a) prevents actual heart attacks or strokes. The Phase 1 and 2 trials evaluated safety and efficacy, not long-term patient outcomes or survival.

Furthermore, the long-term safety profile of persistently targeting this specific RNA remains under investigation. We do not yet have definitive data on whether this direct intervention prevents major cardiovascular events over continuous use, making long-term observation essential.

Looking Ahead

To address these clinical gaps, researchers are currently running the ACCLAIM-Lp(a) Phase 3 trial. This randomised study will evaluate whether the therapy actually reduces major cardiovascular events in patients with established ASCVD or those at high cardiovascular risk.

If the trial succeeds, it could fundamentally alter how clinicians organise treatment for this highly prevalent risk factor. Until the final data arrive, the medical community must wait to see if a direct reducing effect translates into longer, healthier lives.